Skip to content

2027 at other companies

PBH
Prestige Consumer HealthcarePBH
Viatris logo
ViatrisVTRS
Merck & Co. logo
Merck & Co.MRK
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
Abbott logo
AbbottABT
Bausch + Lomb logo
Bausch + LombBLCO

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.53B-59.4%

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%
Debt / equity9.5×-7.0×
Current ratio+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's 2027.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organon's 2027?
Organon (OGN) reported 2027 of $61M in Q1 2026.
How has Organon's 2027 changed year-over-year?
Organon's 2027 increased by 144.0% year-over-year, from $25M to $61M.